Apollo Health Ventures
VC Fund
Berlin, Germany
Apollo Health Ventures is an Early Stage Investment Firm interested in accelerating breakthrough scientific discoveries to the clinic by building life science companies around new therapeutic technologies. Apollo Ventures focuses on assets with the potential to treat, prevent, or even reverse age-related diseases such as Alzheimer's, HeartDisease, Sarcopenia, Frailty, and Cancer, with the ultimate goal of increasing healthy human lifespan. Apollo invests in early stage companies, works with scientists and entrepreneurs to create new ventures, and engages in hypothesis-driven company building.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 45%
- Fund size:
- $180M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Apollo Health Ventures invests in
Stages Apollo Health Ventures invests in
Countries Apollo Health Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexandra Bause
|
|||
Marianne Mertens
|
|||
Marianne Mertens
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Biotechnology 11 (50%)
- Therapeutics 6 (27%)
- Health Care 5 (23%)
- Medical 3 (14%)
- Biopharma 3 (14%)
Stage
- Seed 8 (36%)
- Series A 6 (27%)
- Series B 2 (9%)
- Series C 1 (5%)
Country
- United States 6 (27%)
- United Kingdom 2 (9%)
- France 1 (5%)
- Germany 1 (5%)
- Switzerland 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alexandra Bause
Co-Founder, Investment Director and Head of VentureLabs
|
Co-Founder, Investment Director and Head of VentureLabs | Total investments: 0 | Find email | |
Jens Eckstein
Managing Partner
|
Managing Partner | Total investments: 18 | Find email | |
|
Marianne Mertens
Partner
|
Partner | Total investments: 0 | Find email | |
|
Marianne Mertens
Partner
|
Partner | Total investments: 5 | Find email | |
Nils Regge
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 4 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Bionyra
|
Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases. | $165M / Series A / Jun 22, 2026 | |
Cognito Therapeutics
|
Cognito Therapeutics develops neurotechnology therapies designed to treat neurodegenerative diseases by stimulating specific brain activity patterns. The company focuses on noninvasive therapeutic systems that use synchronized visual and auditory stimulation to influence neural activity associated with cognitive function and brain health. Itstechnology platform, Spectris, is designed to evoke gamma-frequency brain waves, which play a role in learning, memory, and communication between neurons. The platform delivers controlled light and sound signals through a wearable device to trigger gamma oscillations in the brain, a pattern of neural activity that is disrupted in conditions such as Alzheimer’s disease. By restoring this activity, the therapy aims to support processes related to synaptic function, myelin integrity, and neural connectivity.Cognito Therapeutics conducts clinical research and trials to evaluate how its neuromodulation technology affects cognitive performance, brain structure, and functional abilities in patients with neurodegenerative disorders. The company studies the biological effects of sensory stimulation on brain pathways, immune responses, and neural signaling networks associated with disease progression. Through its research programs and device development, Cognito Therapeutics produces medical technologies intended for clinical treatment and investigation of neurological conditions that affect memory, cognition, and daily functioning. | $105M / Series C / Mar 05, 2026 | |
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $55M / Series B / Dec 16, 2025 | |
Scripta Therapeutics
|
Scripta Therapeutics operates as a bio-tech company, that delivers transformative therapeutics through cutting edge technology. | $12M / Seed / Nov 13, 2025 | |
Therini Bio
|
Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation. | $39M / Series A / May 14, 2025 | |
HAYA Therapeutics
|
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $65M / Series A / May 08, 2025 | |
Auron Therapeutics
|
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M / Series B / Feb 04, 2025 | |
Refoxy Pharma
|
Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity. | $9.6M / Seed / Dec 04, 2024 | |
Booster Therapeutics
|
Booster Therapeutics is a biotech business that regulates cellular homeostasis and develops treatments for age-related disorders. | $15M / Seed / Oct 10, 2024 | |
|
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $50M / Series A / Mar 28, 2024 | |
| See all 22 investments → | |||
Co-Investors
4See Ventures
3 deals together
Broadview Ventures
3 deals together
Eli Lilly
3 deals together
Hevolution Foundation
3 deals together
Schroder Adveq
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Apollo Health Ventures invest in?
Apollo Health Ventures invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Seed and Series A stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Apollo Health Ventures?
Public channels for Apollo Health Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Apollo Health Ventures?
The team at Apollo Health Ventures includes Alexandra Bause (Co-Founder, Investment Director and Head of VentureLabs), Jens Eckstein (Managing Partner) and Marianne Mertens (Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
